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Cancer therapies are associated with increased infertility risk due to accelerated reproductive aging. Oxidative stress (OS) is a
potential mechanism behind ovarian toxicity by cyclophosphamide (CPM), the most ovotoxic anticancer drug. An important
sensor of OS is SIRT1, a NAD+-dependent deacetylase which regulates cellular defence and cell fate. This study investigated
whether the natural carotenoid crocetin and the synthetic compound AS101 protect the ovary against CPM by modulating
SIRT1 and mitochondrial markers. We found that the number of primordial follicles of female CD1 mice receiving crocetin plus
CPM increased when compared with CPM alone and similar to AS101, whose protective effects are known. SIRT1 increased in
CPM mouse ovaries revealing the occurrence of OS. Similarly, mitochondrial SIRT3 rose, whilst SOD2 and the mitochondrial
biogenesis activator PGC1-α decreased, suggesting the occurrence of mitochondrial damage. Crocetin and AS101 administration
prevented SIRT1 burst suggesting that preservation of redox balance can help the ovary to counteract ovarian damage by CPM.
Decreased SIRT3 and increased SOD2 and PGC1-α in mice receiving crocetin or AS101 prior to CPM provide evidence for
mitochondrial protection. Present results improve the knowledge of ovarian damage by CPM and may help to develop
interventions for preserving fertility in cancer patients.
1. Introduction
Novel management strategies have led to increased rates of
cancer survivors throughout the past three decades highlight-
ing the need of posttreatment care to improve the patient’s
quality of life [1]. For females, a serious long-term side effect
of cancer therapies is the increased infertility risk due to
accelerated reproductive aging leading to premature ovarian
failure (POF) [2]. Hence, fertility preservation has been inte-
grated into oncology practice giving rise to oncofertility, a
new discipline that bridges oncology and reproductive
research [3]. Current strategies are based mainly on assisted
reproductive technologies (i.e., oocyte-embryo cryopreserva-
tion and ovarian tissue cryopreservation/transplantation)
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that are suitable only for few categories of patients or are
still experimental [1]. Suppression of the pituitary-gonadal
axis via GnRH analogue administration has been so far the
most feasible intervention although results of recent clinical
trials are contradictory [4–6]. One of the possible reasons
for limited progress in the field is the partial understanding
of the mechanistic events that could be targeted to provide
protection or repair from ovotoxicity (reviewed by [7, 8]).
Similar to women, studies in rodents revealed that the
predominant effect of anticancer cytotoxic treatments is
the total or partial loss of the finite pool of dormant oocytes
in the primordial follicles at concentrations relevant to
human exposures [9–11].
Clinically, the most ovotoxic drugs are the alkylating
agents including cyclophosphamide (CPM). This drug is
widely used for the treatment of cancers affecting females in
their childhood or reproductive age, including breast cancer
[5, 12]. It is also used as an immunosuppressant for autoim-
mune diseases and multiple sclerosis and preventing organ
transplant rejection [13–15]. CPM requires hepatic bioacti-
vation to form the active metabolite phosphoramide mustard
(PM) that covalently binds to DNA, inducing DNA-DNA,
DNA-protein crosslinks, and DNA double-strand breaks
(DSB). Both oocytes and granulosa cells show these types of
DNA damage following in vitro exposure of ovaries and cells
[16, 17]. The activation of an ovarian DNA damage repair
response has been reported in terms of early upregulation
of specific genes including ATM (ataxia telangiectasia
mutated) in neonatal rat ovaries exposed to PM. This
response was associated with increased levels of proapoptotic
genes and follicle loss by apoptosis [18, 19]. In addition to
apoptosis, CPM-induced DNA damage may also cause acti-
vation of follicle dormancy by stimulating the PI3K/PTEN/
AKT signalling pathway. The upregulation of AKT signalling
would lead to phosphorylation/inhibition of FOXO3a tran-
scription factor in primordial follicles and subsequent dis-
ruption of the regulatory mechanism underlying dormancy
of primordial follicles [20, 21]. In vivo administration of
AS101 (ammonium trichloro(dioxoethylene-o,o′)tellurate),
an immunomodulator with antitumor effects [22], inhibits
AKT phosphorylation/activation induced by CPM and pre-
vents the loss of primordial follicles. Beneficial effects on
growing follicles were also observed [20].
A further potential mechanism behind CPM ovarian
toxicity is oxidative stress (OS) (reviewed by [23, 24]). In a
human granulosa cell line, exposure to a pre-activated
CPM metabolite results in depletion of glutathione (GSH),
a crucial cellular antioxidant, a rise in reactive oxygen spe-
cies (ROS) and apoptosis. Consistently, GSH exposure
reduces CPM-induced granulosa cell toxicity [25]. More-
over, in vivo administration of CPM has been associated
with low GSH content, reduced SOD2 (Superoxide dismut-
ase 2) activity, and increased lipid peroxidation in rat ovaries
[26, 27]. Oxidative stress is thought to arise from biotrans-
formation/detoxification of PM as described by Madden
and Keating [28] in in vitro ovarian models.
An important sensor of cell redox state is SIRT1, one of
the seven members of the mammalian sirtuin family,
NAD+-dependent enzymes with deacetylase and/or mono-
ADP-ribosyl transferase activity [29–33]. By its numerous
targets, SIRT1 orchestrates cellular defence and repair mech-
anisms and controls cell fate avoiding survival of damaged
cells [34]. Mouse oocytes upregulate SIRT1 gene to cope
with OS supporting a pivotal role for this protein in the
early adaptive response to OS [35, 36]. In many tissues,
SIRT1 abundance can be regulated by modulating the
mRNA stability by the RNA-binding protein HuR (Hu anti-
gen R). Indeed, HuR stabilises SIRT1 transcripts and pro-
motes their polyribosome engagement for active translation
[37]. An important SIRT1 substrate is PGC1-α (peroxisome
proliferator-activated receptor gamma coactivator 1-alpha),
an activator of mitochondrial biogenesis and a key regulator
of mitochondrial gene expression required to meet energetic
demands during cellular stresses [38]. These activities under
stress conditions are also regulated by the mitochondrial
sirtuin, SIRT3, throughout a complex network [39–41].
Although OS has been proposed as an important mech-
anism involved in CPM ovarian toxicity, the efficacy of
in vivo antioxidant interventions has been poorly investi-
gated [26, 27]. Systemic treatment with some carotenoids
has been largely demonstrated to protect nonmalignant tis-
sues against CPM toxicity by promoting antioxidant and
anti-inflammatory effects [42–46]. Crocetin (8,8′-diapocar-
otenedioic acid) belongs to the bioactive family of caroten-
oids derived from the stigmas of Crocus sativus (saffron
spice) and well-known in traditional medicine [47, 48]. Cro-
cetin is known to act as an effective free radical scavenger
and lipid peroxidation inhibitor. Importantly, it effectively
improved antioxidant biomarkers and attenuated inflamma-
tory reaction [49–53]. Furthermore, crocetin is known to
exert potent antitumour effects [54–56].
Based on the above observations, this work investigates
whether (i) oral administration of the natural carotenoid
crocetin prevents gonadotoxicity in female mice; (ii) SIRT1
is involved in the molecular pathways activated in the early
ovarian response to CPM; and (iii) the protective effects of
crocetin influence SIRT1 expression and mitochondrial
toxicity induced by CPM. To address the first point, we tested
the ability of crocetin to mitigate CPM-induced follicle loss,
primordial follicle activation, and subfertility. To clarify
SIRT1 involvement, we relied on a human granulosa cell line
previously used to test CPM toxicity [25, 57], prior to inves-
tigation on the animal model. To gain knowledge about cro-
cetin efficacy and mechanism of action, the fertoprotective
agent AS101, known to protect the mouse ovary against
CPM, was also tested [20].
2. Materials and Methods
2.1. Cyclophosphamide, Crocetin, and AS101 Preparation.
Cyclophosphamide (CPM) was obtained from Baxter, Rome,
Italy. A solution of CPM at a concentration of 25mg/mL in
PBS (pH7.4) was freshly prepared.
Crocetin isolation was performed by crocetin esters [56]
and purified by an internal method of the Verdù Cantò
Saffron Spain Company (Novelda, Alicante, Spain). Crocetin
quantification was analysed by the reverse-phase HPLC tech-
nique. Twenty μL of crocetin aqueous solution (252mg/L)
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was filtered through a 0.45μm PTFE filter and injected into
an Agilent 1200 chromatograph (Palo Alto, CA) operating
with a 150mm× 4.6mm i.d. and 5μm Phenomenex (Le
PecqCedex, France) Luna C18 chromatographic column,
at 30°C. Eluents were water (A) and acetonitrile (B) with
the following elution gradient: 20% B, 0–5min; 20–80%
B, 5–15min; 80% B, 15–18min; and 20%B, 18–30min.
The flow rate was 0.8mL·min−1, and the DAD detector
(Hewlett Packard, Waldbronn, Germany) was set at
440nm for the detection of cis/trans crocetin. Crocetin
quantification was estimated using the method based on
the extinction coefficient and the related area calculated
according to [58, 59].
AS101 was obtained from Tocris Biosciences, Bristol,
UK. A solution of AS101 at a concentration of 150mg/mL
in PBS (pH7.4) was freshly prepared.
2.2. Mice and Study Design. A total of 69 young CD-1 female
mice aged 4 to 8 weeks (Charles River Italia s.r.l., Calco, Italy)
were used in the present study. All the experiments were
carried out in accordance with the guidelines for the care
and use of laboratory animals approved by the Animal Care
Committee of the University of L’Aquila. Mice were ran-
domly divided into four groups:
(i) CTRL: normal control mice were maintained on a
standard laboratory pellet diet and water ad libitum,
without administering medicine for 15 consecutive
days. On the 15th day, they received a single intra-
peritoneal injection of 100μL of PBS.
(ii) CPM: mice were maintained on a standard labora-
tory pellet diet and water ad libitum, without admin-
istering medicine for 15 consecutive days. On the
15th day, they received a single intraperitoneal injec-
tion of CPM (100mg/kg).
(iii) CRO+CPM:mice received crocetin extract (100mg/
kg, [56]) by using a gastric gavage and were allowed
free access to a standard laboratory pellet diet and
water for 15 consecutive days. On the 15th day,
they received a single intraperitoneal injection of
100μL of CPM (100mg/kg).
(iv) AS101+CPM: mice received AS101 (10μg per
mouse, [20]) by intraperitoneal injections on alter-
nate days and were allowed free access to a standard
laboratory pellet diet and water for 15 consecutive
days. On the 15th day, they received a single intra-
peritoneal injection of 100μL of CPM (100mg/kg).
At 12 h and 24 h after the administration of CPM, three
mice of each group were sacrificed by cervical dislocation
(in accordance with the provisions of the EEC regulation
86/609), and ovaries were immediately placed into liquid
nitrogen and then stored at −80°C for further analysis. The
remaining animals were sacrificed 7 days post CPM, and
ovaries were fixed in 4% paraformaldehyde (PFA) at 4°C
overnight and paraffin-embedded. Ovarian sections of 5μm
were prepared for further analysis.
2.3. Haematoxylin and Eosin Staining and Follicular
Classification. Ovarian sections were stained with haematox-
ylin and eosin (H&E) and analysed under a light microscope
for differential follicle counts. Briefly, blind follicle counts
were conducted on every fifth section of entire ovaries by
two independent researchers. Follicle stage was classified
according to [60]. The classification is based on (i) the size
of the oocyte in follicles of different stages of development;
(ii) the size of the follicle defined by the number of cells con-
stituting the follicular envelope, and (iii) the morphology of
the follicle. Primordial follicles are quiescent follicles charac-
terized by a small oocyte, with a diameter of less than 20μm,
with up to 20 follicle cells attached to its surface on the largest
cross-section. Growing follicles include primary follicles,
characterized by one complete ring of follicle cells (21 to 60
cells on the largest cross-section) that surround a growing
oocyte (diameter between 20 and 70μm); secondary follicles,
with two or three layers of follicle cells (61 to 200 cells on the
largest cross section) surrounding a growing oocyte (diame-
ter between 20 and 70μm); and antral follicles, a fully grown
oocyte (diameter 70μm) surrounded by many layers of folli-
cle cells separated by scattered areas or a cavity containing
follicle fluid. Only those follicles in which the nucleus of the
oocyte was clearly visible were considered and taken into
account. The numbers were then multiplied by 5 in order
to obtain an estimate of total follicle numbers per ovary [61].
2.4. Mating Protocol. The mating protocol proposed by
Meirow et al. [10] in order to avoid the risk of CPM-related
foetal malformations was selected. Briefly, twelve weeks after
CPM, female mice from each experimental group were
mated with untreated proven fertile males (two females to
one male) for 1 week. Then, the females were separated for
the duration of pregnancy (21 days) until 3 weeks after the
birth of the litter. Females were remated every 8 weeks for a
total of three successive mating rounds. The mean number
of pups per mouse was counted after each mating round in
all experimental groups.
2.5. In Vitro Culture of Granulosa Cells and Proliferation
Analysis by BrdU Incorporation. COV434 cells are mitotic
human granulosa cells used for in vitro studies of cytotoxic
actions of chemotherapy drugs [25, 57, 62]. COV434 cells
(Sigma-Aldrich, St. Louis, MO) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM), supplemented with
10% foetal bovine serum (FBS) and 1% penicillin/streptomy-
cin and 2mM L-glutamine. Cultures were maintained at
37°C in a CO2 incubator with a controlled humidified atmo-
sphere composed of 95% air and 5% CO2. FBS, DMEM,
penicillin/streptomycin, and all other reagents used for cell
culture studies were purchased from Euroclone (Pero, Italy).
Cells were seeded at a density of 2.5× 104 cells per well in 96-
well plates and exposed to the active CPM metabolite
phosphoramide mustard (PM, Niotech, Bielefeld, Germany)
at concentrations ranging from 10 to 100μM. The effects of
PM on cell proliferation were assessed using the Cell
Proliferation BrdU ELISA (Roche Applied Science,
Mannheim, Germany) according to the manufacturer’s
instructions. Briefly, after 60 h, 10μL of BrdU reagent was
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added to each well and the cells were cultured for 12 h at
37°C. After 72 h of culture, cells were fixed with Carnoy’s fix-
ative (3 : 1 methanol: glacial acetic acid) for 20 minutes at
−20°C. DNA was partially digested with nucleases to allow
the antibody to access BrdU; then cells were incubated with
a monoclonal antibody to BrdU, followed by incubation with
the anti-BrdU antibody labelled with peroxidase. Finally, the
peroxidase substrate ABTS was added, in order to obtain a
coloured reaction product. The absorbance of the samples
was measured at approximately 405nm with a standard
microplate reader (Sunrise, Tecan, Männedorf, Switzerland).
2.6. Quantitative Real-Time PCR. Granulosa cells were
exposed to 50μM PM for 3 h, 6 h, and 12 h, and total RNA
was extracted using TRIZOL reagent (Life Technologies-
Thermo Fisher Scientific, Waltham, MA, USA) following
the manufacturer’s instructions. 1μg of total RNA was retro-
transcribed in a final volume of 20μL using a cDNA Reverse
Transcription kit (Life Technologies-Thermo Fisher Scien-
tific). 2μL of cDNA was used for q-RT-PCRs using aCFX96
Touch™ Real-Time PCR Detection System (Bio-Rad Labora-
tories, Milan, Italy). Primer sequences were the following:
SIRT1: FW 5′-CAGTGTCATGGTTCCTTTGC-3′ and REV
5′-AGGACATCGAGGAACTACCTG-3′; HuR: FW 5′-GCT
ATGGCTTTGTGAACTACGTG-3′ and REV 5′-TGATGTA
CAAGTTGGCGTCTTTG-3′; and RNA18S: FW 5′-GCAGC
TAGGAATAATGGAATAG-3′ and REV 5′-TGGCAAAT
GCTTTCGCTCTG-3′. mRNA levels were detected using a
KAPA SYBR® FAST qPCR Master Mix (2X) Kit (KAPA
Biosystems, Wilmington, MA, USA) according to the manu-
facturer’s protocol. Gene expression was normalized to the
housekeeping gene RNA 18S. Comparisons in gene expres-
sion were calculated using the 2−ΔΔCt method. Two biologi-
cal replicates were performed, each in technical triplicates.
2.7. Sample Preparation and Western Blot Analysis. Ovarian
tissues were homogenized in RIPA buffer by repeated
freeze/thaw cycles in liquid nitrogen. After centrifugation
(33,000 rpm for 1 h at 4°C), the supernatants were collected
for protein analysis. Protein concentration was determined
by a BCA protein assay kit (Pierce, Rockford, IL, USA). Pro-
tein samples were separated by SDS-PAGE and transferred to
a polyvinylidene difluoride membrane (Sigma-Aldrich).
Nonspecific binding sites were blocked overnight with 5%
not-fat dry milk (Bio-Rad Laboratories) in Tris-buffered
saline containing 0.05% Tween 20 (TBS-T). Membranes were
incubated with rabbit polyclonal anti-pAKT1 (SC-135650,
Santa Cruz Biotechnology Inc., Dallas, TX, USA, 1 : 250), rab-
bit polyclonal anti-pFOXO3a (Ab47285, Abcam, Cambridge,
UK, 1 : 700), rabbit polyclonal anti-SIRT1 (Ab12193, Abcam,
1 : 700), mouse monoclonal anti-HuR (SC-71290, Santa Cruz
Biotechnology Inc., 1 : 250), rabbit polyclonal anti-SIRT3
(Ab86871, Abcam, Cambridge, UK, 1 : 700), rabbit poly-
clonal anti-SOD2 (Ab86087, Abcam, 1 : 1000), rabbit poly-
clonal anti-PGC1-α (SC-13067, Santa Cruz Biotechnology
Inc., 1 : 500), or mouse monoclonal anti-β actin antibody
(Ab8226, Abcam; 1 : 3000) for 1 h at room temperature,
followed by incubation with horseradish peroxidase- (HRP-)
conjugated anti-rabbit (Ab6721, Abcam, 1 : 3000) or anti
mouse (Ab6728, Abcam, 1 : 2000) secondary antibody for
1 h at room temperature. After washing, specific immunore-
active complexes were detected by an ECL kit (Life
Technologies-Thermo Scientific) and Uvitec Cambridge
system (Alliance series, Cambridge, UK). When membrane
reprobing was necessary, stripping was performed by incuba-
tion in Tris-buffered saline (pH6.7) containing 100mM
beta-mercaptoethanol, 2% SDS, at 54°C for 30min.
Immunoreactive bands were normalized to β-actin levels
using ImageJ 1.44p software. Values were given as relative
units (RU). Each experiment was performed in triplicate.
2.8. Statistical Analysis.All data are presented asmean± SEM.
Statistical analysis was assessed by one-way ANOVA
followed by Holm-Sidak multiple comparison. Analyses were
performed using the Sigma Stat software (Jandel Scientific
Corporation, San Rafael, CA, USA). P value < 0.05 was con-
sidered statistically significant.
3. Results
3.1. Pretreatment with Crocetin or AS101 Reduces CPM-
Induced Follicle Loss. To assess the potential of crocetin as
an attenuating agent against CPM toxicity, adult female mice
were treated with a daily dose of 100mg/kg crocetin for 15
days before administration of 100mg/kg CPM. A group of
adult female mice was treated with AS101 (10μg/mouse)
on alternate days beginning 15 days before CPM treatment.
Quantification of the different follicle populations was car-
ried out in the ovaries 1 week after CPM administration. As
shown in Figure 1(a), mice receiving crocetin prior to CPM
retained a number of primordial follicles larger than CPM
alone and not significantly different from untreated controls.
Quantification of primordial follicles also revealed that the
crocetin effect was similar to AS101. A number of growing
follicles in mice receiving crocetin or AS101 prior to CPM
was significantly larger than CPM alone reaching values sim-
ilar to untreated controls.
3.2. Crocetin and AS101 Treatments Rescue Fertility in CPM-
Treated Mice. To confirm that preservation of primordial
follicles observed in CPM-treated mice receiving crocetin or
AS101 was associated with increased fertility, mice from each
experimental group were mated for three rounds. At the time
of mating, all females had normal oestrous cycles, had similar
weight, and appeared healthy. Our data show that a single
dose of 100mg/kg CPM did not affect the reproductive capa-
bility of mice until the third round of mating. At this time, we
obtained no litter from the CPMmice since they were unable
to get pregnant after one week of caging with males. By
contrast, CPM-treated mice receiving crocetin or AS101
got pregnant after all mating rounds and presented a litter
size not significantly different from the control group
(Figure 2).
3.3. Effects of Crocetin and AS101 on PI3K/AKT/FOXO3A
Pathway. To search for molecular mechanisms underlying
protective effects of crocetin, we hypothesized a potential
effect on the PI3K/AKT/FOXO3A pathway underlying
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primordial follicle activation. By looking at the effects at
protein expression level, we found that CPM increased the
activated form of AKT protein (pAKT) phosphorylated by
PI3K and the inactive form of FOXO3a (pFOXO3a)
phosphorylated by pAKT. By contrast, crocetin and AS101
treatment results in reduction of both pAKT and pFOXO3a
when compared with CPM alone (Figures 3(a) and 3(b)).
However, crocetin effect was more pronounced than AS101
and similar to untreated control.
3.4. SIRT1 Protein and Its Regulator HuR Are Increased
during the Early Response to CPM. To investigate the involve-
ment of SIRT1 in the response to CPM, we conducted the
first set of experiments in human granulosa cells aimed to
analyse changes in mRNA levels of SIRT1 and HuR after
3 h, 6 h, and 12 h of PM exposure. At first, we carried out
experiments in order to identify the minimum effective dose
of PM, the active metabolite of CPM. After 72h of treatment,
proliferation was significantly reduced in human granulosa
cells cultured in the presence of 50 μM PM. Since no further
inhibition was observed at 100 μM PM, (P < 0 001,
Figure 4(a)), we employed the dose of 50 μM PM in gene
expression experiments. Then, we analysed the expression
level of SIRT1 and of HuR in COV434 cells exposed to
50 μM PM for 3 h, 6 h, and 12 h. Both genes increased
their expression level in a time-dependent manner, sug-
gesting the activation of the OS response in this cell line
(Figures 4(b) and 4(c)).
In the second set of experiment, mice received CPM and
were sacrificed at 12h and 24 h after CPM treatment. Our
results show that SIRT1 protein level increased at 12h and
doubled its expression at 24h after CPM treatment
(Figure 5(a)). HuR protein increased at 12h after CPM to
decrease at 24 h (Figure 5(b)).
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Figure 2: Crocetin and AS101 treatments rescue fertility in
CPM-treated mice. Reproductive outcomes were assessed over
three successive mating rounds in mice (n = 9, per experimental
group) that received CPM treatment preceded or not by crocetin
or AS101 pretreatment. Litter size was counted after each mating
round. Data represent means± SEM. One-way ANOVA (P < 0 001),
followed by multiple comparison by Holm-Sidak (∗∗∗P < 0 001;
∗P < 0 05).
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Figure 1: Crocetin reduces follicle loss after CPM treatment. (a) Differential follicle count was conducted on ovaries removed from adult
(8 weeks old) female CD1 mice (n = 3, per experimental group) 1 week after CPM treatment preceded or not by crocetin or AS101
pretreatment. Follicles were classified as quiescent primordial follicles or growing follicles. Data represent means± SEM. One-way
ANOVA (P < 0 001), followed by multiple comparison by Holm-Sidak (∗∗∗P < 0 001; ∗P < 0 05). (b) Representative histological
sections of ovaries from the CTRL, CPM, CRO+CPM, and AS101 +CPM groups showing follicle reserve. Scale bars: 400μm.
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3.5. Crocetin and AS101 Prevent the SIRT1 Upregulation
Induced by CPM. In the second set of experiments, we tested
whether crocetin and AS101 act by modulating the early
adaptive response regulated by SIRT1. Our data showed that
crocetin treatment prevented the increased expression of
SIRT1 induced by CPM treatment (Figure 6). Furthermore,
mice receiving crocetin prior to CPM presented a SIRT1
expression level equivalent to untreated controls. AS101
induced a reduced activation of SIRT1 protein produc-
tion in comparison to CPM treatment, but its levels were
enhanced when compared to crocetin and untreated con-
trol mice.
3.6. Crocetin and AS101 Prevent CPM-Induced Changes in
Mitochondrial Markers. To test whether the protective effect
of crocetin was exerted throughout regulation of mitochon-
drial markers, we analysed the expression level of SIRT3,
SOD2, and PCG1alpha. Similar to SIRT1, SIRT3 increased
at 24 h following CPM (Figure 7(a)). Crocetin treatment pre-
vented the SIRT3 increase induced by CPM although SIRT3
amount was lower than that observed in untreated controls.
AS101 treatment promoted a similar effect. Moreover, CPM
was found to significantly reduce SOD2 protein. Both croce-
tin and AS101 treatments attenuated this effect although
SOD2 level was lower than that observed in untreated controls
(Figure 7(b)). Our results also showed that CPM mice pre-
sented lower levels of PGC1-α protein when compared with
control whereas crocetin and AS101 induced a threefold
increase of this protein in comparison to untreated controls
(Figure 7(c)).
4. Discussion
Considering the increment in survival rates of cancer patients
in their childhood or reproductive age, searching for ferto-
protective agents is the main challenge in oncology practice.
Here, we demonstrate for the first time that oral administra-
tion of crocetin, a natural carotenoid derivative and effective
free radical scavenger, attenuates CPM-induced gonadotoxi-
city and modulates molecular pathways involved in the early
ovarian response to this anticancer drug. These observations
provide strong evidence that an imbalance of redox potential
is the main factor underlying CPM-induced ovarian damage.
Moreover, we outlined that crocetin effects at both molecular
and biological levels resembled those by AS101, the most rel-
evant candidate as a fertoprotective agent.
Crocetin, the main bioactive saffron compound [63, 64],
is the hydrolysed active form of crocin, which is the most
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Figure 3: Crocetin reduces CPM-induced phosphorylation of key proteins in the PTEN/PI3K/Akt pathway. Protein analysis was conducted
on ovaries from 8-week-old mice (n = 3, per experimental group) removed 24 hours after a single dose of CPM preceded or not by crocetin
or AS101 pretreatment. Western blots of pAKT (a) and pFOXO3a (b) and representative images (c). Fold change is represented as a bar
graph. Experiments were repeated three times with similar results. One-way ANOVA (P < 0 001), followed by multiple comparison by
Holm-Sidak (∗∗∗P < 0 001; ∗P < 0 05).
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investigated saffron carotenoid. In comparison with crocin,
crocetin is more rapidly absorbed in the intestinal tract and
exhibits greater efficacy [65]. It is well established that the
therapeutic effects of crocetin against some types of cancers,
including breast cancer, have been pointed out [47, 48, 54–
56, 66–69]. Crocetin acts in a dose-dependent manner in
in vitromodels [47, 55, 67, 68]. Oral administration of croce-
tin has been employed in research on mice aimed to investi-
gate its effects against retinal damage [70] and tumour
growth [56, 69]. Crocetin has also been administrated to
healthy adult human volunteers, demonstrating that it is ben-
eficial also in humans [71, 72]. Although only one paper
reported the prevention by crocetin of CPM side effects on
the bladder and liver [73], a plethora of publications reveals
that crocetin can provide protection against OS induced by
toxicants or underlying disorders in numerous organs, tis-
sues, and cells [49–52, 74–78].
Our data show that crocetin protects primordial and
growing follicles from CPM injury and the mechanism
underlying the protective action of crocetin is similar to that
of AS101. Crocetin treatment results in the reduction of the
phosphorylated/activated form of AKT protein (pAKT) and
the phosphorylated/inactive form of FOXO3a (pFOXO3a)
when compared with CPM. According to our results, croce-
tin treatment was more effective in reducing the activation
of the PI3K/AKT/FOXO3a pathway in response to CPM
since pAKT and pFOXO3a levels were lower than that
observed in AS101 although this difference did not result in
higher efficacy in terms of follicle survival. Thus, it would
be suggested that crocetin, similar to AS101, prevents dysreg-
ulation of follicle activation induced by CPM. Nevertheless,
further investigation is needed to clarify whether crocetin,
similar to AS101 [20], is able to reduce follicle apoptosis
induced by CPM.
In addition to its role in follicle activation, FOXO3a is
known to activate an antioxidant response when deacetylated
by SIRT1. However, this function cannot be exerted when
FOXO3a is phosphorylated by AKT. Thus, we can hypoth-
esize that the increased levels of pFOXO3a in CPM ovaries
may compromise the antioxidant response orchestrated
by SIRT1.
SIRT1 plays a critical role in coordinating cellular
response to stress, and SIRT1 levels are upregulated by cellu-
lar stressors, including metabolic, genotoxic, and oxidative
stress [79]. Indeed, in our model of human granulosa cells
sensitive to antiproliferative effects of CPM, Sirt1 and HuR
transcription gradually increases with the same kinetics,
demonstrating the involvement of SIRT1 in the early steps
of cell response to CPM damage. This conclusion has been
confirmed in the animal model where we observed that as
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Figure 4: SIRT1 and HuR mRNA increase after a PM treatment in human granulosa cell. (a) After 72 h of treatment, human granulosa cells
cultured in the presence of 50μM PM showed a significant reduction of proliferation. (b) SIRT1 and (c) HuR mRNA expression levels after
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early as 12h following CPM administration, the ovary acti-
vates an adaptive response based on upregulation of SIRT1
protein that peaks at 24 h. This pattern is preceded by upreg-
ulation of HuR which peaks at 12 h to decrease at 24 h indi-
cating that in response to stress HuR may act transiently to
stabilise SIRT1 transcripts prior to be degraded [80]. Never-
theless, other roles for HuR cannot be excluded. Posttran-
scriptional function of HuR has been described for a wide
number of transcripts bearing AU-rich elements whose turn-
over is critical for cell fate [81–83].
Previous reports described a reduction of SIRT1 levels
in rat ovaries in response to CPM and the protective role
of caloric restriction associated with increased SIRT1
expression [84]. This is not in contrast with our results
since we focused on the evaluation of the early response
assessed before biological damage whereas the reduction of
SIRT1 levels described elsewhere could be related to
depletion of follicle population following CPM treatment.
Moreover, SIRT1 has been recently involved in the regula-
tion of bioenergetics metabolism during folliculogenesis. In
this regard, Cinco et al., [85] observed that oocyte expres-
sion of SIRT1 is increasing during primordial follicle awak-
ening together with a significant increase of NAD+. This is
related to the decreased NADH/NAD+ levels resulting from
the activation of oxidative phosphorylation for energy sup-
ply during growth. Thus, the increased levels of ovarian
SIRT1 during the early phase of CPM damage may be the
cause or the effect of primordial follicle activation leading
to the burnout effect.
Our data showed that both crocetin and AS101 prevented
the increased expression of SIRT1 induced by CPM. This
could be ascribed to their ability to counteract CPM-
induced changes in the redox potential leading to SIRT1
recruitment. However, the observation that levels of SIRT1
in the two groups are not the same would suggest that croce-
tin and AS101 have a different ability to modulate ovarian
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Figure 7: Crocetin and AS101 prevent CPM-induced mitochondrial damage assessed by SIRT3, SOD2, and PGC1-α protein levels in the
ovary. Protein analysis was conducted on ovaries from 8-week-old mice (n = 3, per experimental group) removed 24 hours after a single
dose of CPM preceded or not by crocetin or AS101 pretreatment. Western blots of SIRT3 (a), PGC1-α (b), and SOD2 (c) and
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physiological environment, which influences SIRT1 expres-
sion. The hypothesis of the oxidative basis of CPM ovarian
damage is supported by the finding that crocetin and
AS101 prevented CPM-induced mitochondrial toxicity. In
particular, crocetin and AS101 treatment counteracted the
upregulation of the mitochondrial sirtuin SIRT3 induced by
CPM. SIRT3 is considered a key coordinator of mitochon-
drial energy metabolism under stress conditions by directly
targeting and modulating various processes [39–41] and
downregulating mitochondrial protein synthesis [86].
Further evidence of OS and its mitochondrial basis are the
downregulation of PGC1-α and SOD2 in CPM ovaries and
the observation that these mitochondrial proteins severely
increased their expression following crocetin and AS101
administration.
Therefore, it can be speculated that SIRT1 is recruited in
order to regulate cell fate following CPM injury. In the exper-
imental model proposed here, it seems to fail to orchestrate
an efficient repair in concomitance with SIRT3, probably
because its substrates, such as FOXO3a and PGC1-α, or
downstream effectors, such as SOD2, are impaired. For these
reasons, we propose that SIRT1 could be considered as a
marker of CPM ovarian injury. Given its role as a sensor of
damage and effector of cell fate, caution should be taken in
proposing attenuating therapies based on SIRT1 targeting.
The inhibition of CPM-induced follicle loss by AS101 has
been ascribed to its ability to inhibit AKT activation and
reduce apoptosis in large growing follicles [20]. The finding
that a potent antioxidant such as crocetin exerts similar
effects on the PI3K/AKT/FOXO3a pathway suggests that
AS101 may also act upstream to this pathway by preventing
the OS burst induced by CPM. This hypothesis is also sup-
ported by the observation that, similar to crocetin, AS101
prevents the activation of OS sensors and mitochondrial tox-
icity induced by CPM. It is also important to consider that
beneficial effects by both crocetin and AS101 may be ascribed
to their effects on the whole ovarian microenvironment. In
this regard, crocetin’s ability to increase diffusion of oxygen
through the plasma can contribute to counteract CPM-
induced inhibition of follicular microvascularization [87].
Moreover, anti-inflammatory properties are known for both
these agents [50, 53, 88, 89] although these effects in the
ovary need to be investigated.
The present study represents a contribution to previous
evidence in animal models about the use of saffron bioactive
molecules in the fertility field. Recent investigations have
revealed that crocetin and its derivative crocin have beneficial
effects on in vitro oocyte maturation, sperm quality, and
fertilization [90–94]. Moreover, crocin has been described
to protect male gonad against CPM toxicity [46].
In conclusion, we speculate that the ovarian adaptive
response toCPMconsists in a complex network involving oxi-
dative stress, SIRT1, and mitochondrial damage (Figure 8).
Finally, due to its efficacy in the animal model and its anti-
cancer properties and low toxicity in humans, this work
demonstrates for the first time that crocetin presents all
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Figure 8: Possible mechanisms through which crocetin and AS101 reverse the early adaptive response of the ovary to CPM. Based on our
results and current literature, CPM causes the activation of the PI3K/AKT/FOXO3A signalling pathway that ends with the activation of
primordial follicles (“burnout” hypothesis). Increased oxidative stress, which probably arisen from reduced GSH due to ovarian PM
detoxification, is evidenced by reduced SOD2 levels and upregulation of the OS sensors SIRT1 and SIRT3. Upregulation of SIRT1 may
contribute to CPM-induced follicle activation; upregulation of SIRT3 along with reduction of PGC1-α and SOD2 marks the CPM-induced
mitochondrial damage. By contrast, the finding that crocetin and AS101 exert fertoprotective effects, prevent SIRT1 and SIRT3 rise, and
maintain pFOXO3a, PGC1-α, and SOD2 levels provides evidence for a link between the burnout hypothesis, oxidative stress, and
mitochondrial damage.
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the characteristics required for a natural fertoprotective
agent to be included in future clinical studies.
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